CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked vigilantly but unsuccessfully to produce an one-time therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll ever be used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past several shares. The 1st CytoDyn article of mine, “CytoDyn: What In order to Do When It’s Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing picture in the Uptick Newswire employment interview that I came away with a poor opinion of the business.

Irony of irony, my poor impression of the company has grown steadily, though the disappointment has not been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > six bagger yet still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for the treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV- infected subjects. Today’s payment of $3.5 zillion transfers ownership of this technology and also associated intellectual property from Progenics to CytoDyn, and also roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 zillion) plus the first brand new drug program approval ($5 million), as well as royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and many indications, it has this single treatment as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple presentations and multiple publications.

Might it all be smoke and mirrors? That is a question I’ve been asking myself from the really beginning of the interest of mine in this particular organization. Judging by the multiples of a huge number of several responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a classic battleground, or even some may say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News